PKTXOTCPharmaceutical PreparationsFiscal year ends December 31

ProtoKinetix, Inc.

Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-K on Sep 3, 2026

$0.00+0.00 (0.00%)

Close on Oct 16, 2026

Market cap: $78.61K
P/E (TTM): –
Dividend yield: –

ProtoKinetix, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Revenue	–	–	–	–	–	–	–	–	–	–	–	0	0	0	0	0	–	–	–	–
Research & Development	0.11	0.10	0.11	0.45	0.44	0.53	0.37	0.34	0.30	0.45	0.16	0.01	0.07	0	0.12	0.16	–	–	–	–
General & Administrative	0.06	0.06	0.10	0.16	0.32	0.21	0.28	0.08	0.11	0.10	0.13	0.14	0.10	0.12	0.20	0.21	–	–	–	–
Operating Expenses	0.39	0.36	0.42	1.91	2.33	7.64	4.20	1.22	1.51	1.52	1.26	0.42	0.45	0.20	0.92	1.40	–	–	–	–
Operating Income	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.20	-0.92	-1.40	–	–	–	–
Interest Expense	–	–	–	–	–	–	0	0.00	0.00	0.00	0.00	0.03	0.03	0.02	0.01	0.02	–	–	–	–
Other Non-Operating Income	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.20	-1.23	–	–	–	–	–
Legal Settlements	–	–	–	–	–	–	–	–	–	–	–	0.19	–	–	–	–	–	–	–	–
Pretax Income	–	–	–	–	–	–	–	–	–	–	–	–	-0.45	-0.20	-1.23	-1.39	–	–	–	–
Income Tax Expense	0	0	0	–	0	0	0	0	–	–	–	–	–	–	–	–	–	–	–	–
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0	0	–	–	–	–
Net Income incl. Noncontrolling Interests	–	-0.36	-0.42	-1.91	-2.33	-7.64	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-0.39	-0.36	-0.42	-1.91	-2.33	-7.64	-4.20	-1.22	-1.51	-1.52	-1.25	-0.17	-0.45	-0.20	-1.23	-1.39	-1.27	-1.55	-2.73	-1.97
Net Income to Common	–	–	-0.42	-1.91	-2.33	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	0.00	0.00	-0.01	-0.01	0.00	-0.03	-0.02	0.00	-0.01	-0.01	-0.01	0.00	0.00	0.00	-0.01	-0.02	–	–	–	–
EPS (Diluted)(per share)	0.00	0.00	-0.01	-0.01	0.00	-0.03	-0.02	0.00	-0.01	-0.01	-0.01	0.00	0.00	0.00	-0.01	-0.02	–	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	386	359	333	307	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	386	359	333	307	292	279	269	256	247	222	198	172	137	129	94	75	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -123.0%

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.26
Dividend yield: –